Addex Therapeutics Ltd. announced that it has terminated the Phase 2b/3 study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease (PD-LID) due to the slow recruitment of patients. This has been attributed to the consequences of COVID-19 related patient concerns about participation in clinical studies as well as staffing shortages and turnover within study sites.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.075 CHF | +9.97% | +19.05% | +63.04% |
Apr. 30 | European Equities Traded in the US as American Depositary Receipts Decline | MT |
Apr. 29 | Sector Update: Health Care Stocks Edge Higher Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.04% | 10.62M | |
+22.81% | 46.81B | |
+46.56% | 41.29B | |
-1.88% | 41.37B | |
-6.20% | 28.87B | |
+11.33% | 26.06B | |
-21.00% | 19.13B | |
-1.43% | 11.96B | |
+30.73% | 12.39B | |
-0.48% | 12.08B |
- Stock Market
- Equities
- ADXN Stock
- News Addex Therapeutics Ltd
- Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson's Disease due to Slow Recruitment Rate